Kubo A, Nakamura K, Sammiya T, Katayama M, Hashimoto T, Hashimoto S, Kobayashi H, Teramoto T
Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
Eur J Nucl Med. 1993 Feb;20(2):107-13. doi: 10.1007/BF00168869.
Neutral phospholipid vesicles (VesCan), which had been prepared for clinical use, were loaded with 37 MBq indium-111 and administered to seven patients with malignant tumours. The median lipid dose was 2.0 mg/kg. Sequential images showed rapid blood clearance at the early stage, with homogeneous uptake of 111In-labelled VesCan (111In-labelled V-liposomes) in the liver and spleen. Dosimetric estimates for these organs were 1.2 and 1.5 mGy/MBq, respectively, with a whole-body exposure dose of 0.076 mGy/MBq. Total renal excretion of 111In was less than 10% of the injected dose, occurring mainly as 111In-EDTA in three patients. Gamma camera images 24-48 h after administration revealed increased activity in the tumours of four patients. 111In-labelled V-liposomes may enable the demonstration of the tumour site without toxicity and with radiation doses comparable to other radionuclide imaging techniques.
已制备用于临床的中性磷脂囊泡（VesCan），装载了37 MBq铟-111，并给予7例恶性肿瘤患者。脂质剂量中位数为2.0 mg/kg。序列图像显示早期血液清除迅速，肝脏和脾脏中111In标记的VesCan（111In标记的V-脂质体）摄取均匀。这些器官的剂量学估计分别为1.2和1.5 mGy/MBq，全身暴露剂量为0.076 mGy/MBq。111In的总肾排泄量小于注射剂量的10%，主要以111In-EDTA形式出现在3例患者中。给药后24 - 48小时的γ相机图像显示4例患者肿瘤部位活性增加。111In标记的V-脂质体可能能够在无毒性且辐射剂量与其他放射性核素成像技术相当的情况下显示肿瘤部位。
